Abstracts tagged "SLE"

Abstract Number: 1294 • 2014 ACR/ARHP Annual Meeting
Gender Differences in the Lupus Nephritis Biomarkers in Children
Khalid Abulaban¹, Hermine Brunner², Michael Bennett³, Shannen L. Nelson⁴, Jun Ying⁵ and Prasad Devarajan³, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵University of Cincinnati, Cincinnati, OH
Background/Purpose: Lupus nephritis (LN) is frequently associated with a poor long-term prognosis. The non-invasive traditional measures of LN (LN-TM) currently used to monitor LN have…
Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Peter E. Lipsky, Matthew Ryals, Jacob Smearman, Victoria Soler and Amrie Grammer, AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…
Abstract Number: 2841 • 2014 ACR/ARHP Annual Meeting
Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide
Belinda A. Waltman¹, Kimberly E. Taylor², Julio Molineros³, Sarah French⁴, Joanne Nitiham¹, Jennifer Kelly³, Adam Adler⁵, Judith A. James³, Swapan Nath⁶, Marta Alarcon-Riquelme^3,7 and Lindsey A. Criswell¹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷GENYO. Center for Genomics and Oncological Research, Granada, Spain
Background/Purpose: Substantial epidemiologic evidence demonstrates that SLE disproportionately affects minority patients in terms of incidence, prevalence, and disease severity. European ancestry has been associated with…
Abstract Number: 2623 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis
Shonda A Foster¹, Emily Durden², Brett Maiese², Sarah Al Sawah¹ and Kathleen Solotkin¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Truven Health Analytics, Bethesda, MD
Background/Purpose: Currently, there is not a standard treatment algorithm for the management of Systemic Lupus Erythematosus (SLE); however, there are medications that may be considered…
Abstract Number: 1813 • 2014 ACR/ARHP Annual Meeting
DNA Sensors Regulate Inflammation in a Model of Autoimmune Arthritis
Rebecca Baum¹, Shruti Sharma², Sudesh Pawaria³, Susan Carpenter⁴, Katherine A. Fitzgerald⁵, Ann Marshak-Rothstein⁶ and Ellen M. Gravallese⁷, ¹Cell Biology, University of Massachusetts Medical School, Worcester, MA, ²Department of Medicine - Infectious Diseases Division, University of Massachusetts Medical School, Worcester, MA, ³Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, ⁶Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ⁷Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Innate immune sensors such as cytosolic DNA sensors and toll-like receptors (TLRs) detect viral or bacterial DNA, resulting in production of proinflammatory cytokines and…
Abstract Number: 1209 • 2014 ACR/ARHP Annual Meeting
Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase
Hao Li^1,2, Qi Wu¹, PingAr Yang¹, Zheng Wang³, Jun Li¹, Bao Luo¹, Jeffrey C. Edberg¹, Hui-Chen Hsu¹, John D. Mountz^1,4 and Robert P. Kimberly on behalf of PROFILE investigators⁵, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, ⁴Birmingham VA Medical Center, Birmingham, AL, ⁵Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Ibrutinib, a Btk kinase activity inhibitor, is a novel inhibitor under development for autoimmune disease therapy. We have shown that Btk was significantly upregulated…
Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Amy Miles¹ and Janet E. Pope², ¹Medicine, University of Western Ontario and U of Toronto, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…
Abstract Number: 2842 • 2014 ACR/ARHP Annual Meeting
An Anti CD123 Monoclonal Antibody (CSL362) Depletes Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated IFNα Production and IFNα-Inducible Gene Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
Shereen Oon^1,2,3, Nicholas Wilson^4,5 and Ian Wicks^1,2,3, ¹Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ²Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ³Medical Biology, The University of Melbourne, Melbourne, Australia, ⁴Cell Biology and Physiology, CSL Limited, Melbourne, Australia, ⁵Honorary appointment, The University of Melbourne, Melbourne, Australia
Background/Purpose Plasmacytoid dendritic cells (pDCs) contribute to systemic lupus erythematosus (SLE) pathogenesis by producing Type 1 interferon (IFN), most likely induced by endosomal Toll like…
Abstract Number: 2432 • 2014 ACR/ARHP Annual Meeting
Nutritional Assessment in Patients with Systemic Lupus Erythematosus and Systemic Sclerosis
Sabrina Vagnani¹, Chiara Tani², Linda Carli³, Francesca Querci³, Alessandra Della Rossa³, Anna d'Ascanio^3,4, Ilaria Ermini⁵, Marco Ceroti⁵, Saverio Caini⁵, Domenico Palli⁵, Stefano Bombardieri⁶ and Marta Mosca³, ¹Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Internal Medicine, University of Pisa, Pisa, Italy, ⁵Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence, Itay., Florence, Italy, ⁶Rheumatology Unit, Pisa, Italy
Background/Purpose Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) can be both associated with various degrees and types of malnutrition, with different pathogenetic mechanisms. It’s…
Abstract Number: 1825 • 2014 ACR/ARHP Annual Meeting
Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus
Patricia Vega-Fernandez¹, Shana Vanderburgh², Deborah M. Levy³, Frank A. Zelko⁴, Eyal Muscal⁵, Natasha M. Ruth⁶, Adam M. Huber⁷, Marisa S. Klein-Gitelman⁸, Kasha Wiley⁹, Wenjie Zheng¹⁰, Lori B. Tucker¹¹, Tresa Roebuck-Spencer¹², Jun Ying¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Rheumatology, Texas Children's Hospital, Houston, TX, ⁶Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ¹²Cognitive Science Research Center, University of Oklahoma, Norman, OK, ¹³Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹⁴PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Patients with childhood-onset SLE (cSLE) may experience neuropsychiatric SLE (NPSLE) manifested as neurocognitive dysfunction (NCD). Formal neurocognitive testing (FNCT) is the most accepted method…
Abstract Number: 1202 • 2014 ACR/ARHP Annual Meeting
Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE
Bo Qu¹, Jianchang Cao², Feifei Zhang² and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Systemic lupus erythematosus (SLE) is characterized by the uncontrolled inflammation along with over produced inflammatory cytokines, among which type I interferon (IFN) is recognized…
Abstract Number: 670 • 2014 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Elisabet Svenungsson¹, Magnus Axelsson² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²AlbaNova, Stockholm University, Stockholm, Sweden
Background/Purpose B cells have a central role in Systemic Lupus Erythematosus (SLE) and autoantibody production. B-Lymphocyte Stimulator (BLyS) is important for the activation and maintenance…
Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 2182 • 2014 ACR/ARHP Annual Meeting
Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases
Alexandra Antonioli¹, Brandon Renner², Joshua Thurman³, V. Michael Holers⁴ and Jonathan Hannan⁴, ¹Department of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Renal Division, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Complement plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) wherein inappropriate activation of complement leads to substantial tissue damage, especially…
Abstract Number: 1668 • 2014 ACR/ARHP Annual Meeting
Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis
Jasvinder A. Singh¹, Haiyan Qu², Jinoos Yazdany³, W. Winn Chatham², Maria Dall'era⁴ and Ricahrd Shewchuk⁵, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies suggest that adherence to medications for lupus nephritis is low. However, there are limited data available on the barriers that patients with lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].